McKesson claims the CytoCare is the only proven automation solution for compounding hazardous IVs used for chemotherapy and monoclonal antibody therapy.
The new technology will enable the 800-bed facility to meet the anticipated growth within its Cancer Services department without requiring additional staff.
CytoCare is designed to improve staff safety by minimising exposure to hazardous medications while increasing efficiency by enabling optimal workflow.
The level of automation, throughput and space requirements of the solution are specifically designed to work well within a hospital’s current pharmacy operations.
OhioHealth system vice president of Pharmacy Charles McCluskey said that their pharmacy technicians prepare approximately 500 chemotherapy IVs each month for inpatients and their outpatient cancer facility, and a pharmacist checks each preparation.
"With CytoCare, we can more efficiently prepare the IVs while reducing our technicians’ exposure to hazardous drugs and reducing the potential for manual compounding errors," McCluskey said.